Allograft loss in renal transplant recipients with Fabry's disease activated protein C resistance

Transplantation

Volumn 69, Issue 10, 2000, Pages 2099-2102

  Friedman, Gary S ^a   Wik, Daniel ^d   Silva, Linda ^d   Abdou, J C ^d   Meier Kriesche, H U ^c   Kaplan, Bruce ^b   Bonomini, Luigi ^a   DeFranco, Penny ^a   Lyman, Neil ^a   Mulgaonkar, Shamkant ^a   Jacobs, Martin ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d S Georges University Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; CLINICAL ARTICLE; COMORBIDITY; FABRY DISEASE; GRAFT REJECTION; HLA TYPING; HUMAN; HYPERCOAGULABILITY; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0034720541     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005270-00022     Document Type: Article

References (27)

1. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry's disease. Dementia Geriatric Cognitive Disord 1997; 8 (4): 252.
2. Utsumi D, Yamamoto N, Kase R. High incidence of thrombosis in Fabry's disease. Intern Med 1997; 36 (5): 327.
3. Chang HS, Ro LS, Chen ST: Fabry's disease: report of a case. J Formosan Medical Association 1995; 94(6): 346-350.
4. Deschiens MA, Conrad J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerbral venous thrombosis. Stroke 1996; 27: 1724.
5. Gaussem P, Siguret V, Aiach M. Evaluation of hemostasis in venous thromboembolism pathology. Ann Biol Clin 1998; 56 (1): 49.
6. Aiaach N, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S. Protein C and protein S deficiencies. Semin Hematol 1997; 34 (3): 205.
7. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73 (1): 87.
8. Handin RI. Disorders of coagulation and thrombosis. Harrison's principles of internal medicine, chapter 60, pg. 339, 14th ed. 1998.
9. Hoerl HD, Tabares A, Kottke-Marchant K. The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature. Vasc Med 1996; 1 (4): 275.
10. Van Boven HH, Reitsma PH, Rosendal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thrombosis Haemost 1996; 75 (3): 417.
11. U.S. Census Bureau. Website: www.census.gov.
12. Huskey RJ. ABO allele frequencies; Website http://wsrv.clas.virginia.edu/~rjh9 u/abofreq.html.
13. Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and HUMAN FACTOR Va by activated protein C. J Biol Chem 1994; 169 (50): 31869.
14. Stoylova S, Mann KG, Brisson A. Structure of membrane-bound human factor Va. FEES Lett 1994; 351 (3): 330.
15. Kappelmayer J, Kunapuli SP, Wyshock EG, Colman RW. Characterization of monocyte-associated factor V. Thrombosis Haemost 1993; 70 (2): 273.
16. Donadi D, Sabadini MG, Capsoni F, et al: Immune function and renal transplantation in Fabry's disease. Proceedings of European Dialysis and Transplant Assoc. Euro Ren Assoc Oxford University Press, Oxford, England, 1985; 21: 686.
17. Heidenreich S, Dercken C, August C, et al. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. JASN 1998; 9 (7): 1309.
18. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem 1996; 271 (23): 13882.
19. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991; 226 (36): 24302.
20. Ledvinova J, Poupetova H, Hanackova A, Pisacka M, Elleder M. Blood group B glycosphingolipids in alpha-galactosidase deficiency (Fabry's disease): influence of secretor status. Biochim Biophys Acta 1997;1345 (2): 180.
21. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with thrombophilia. Transplantation 1998; 65 (7): 936.
22. Crookston KP, Henderson R, Chandler WL. False negative factor V Leiden assay following allogeneic stem cell transplant. Br J Haematol 1998; 100 (3): 600.
23. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92 (9): 3035.
24. Hirshfield G, Collier JD, Brown K, et al. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transplant Surg 1998; 4 (1): 58.
25. Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997; 27: 64 (4): 604.
26. DeLoughery TG. Hemostasis and thrombosis manual. Austin, TX: Landes Bioscience, 1999; 130.
27. DeLoughery TG. Hemostasis and thrombosis manual. Austin, TX: Landes Bioscience, 1999; 130.